Eli Lilly and Co (NEOE:LLY)
C$ 30.07 -0.05 (-0.17%) Market Cap: 1.06 Tn Enterprise Value: 1.10 Tn PE Ratio: 87.15 PB Ratio: 50.94 GF Score: 68/100

Eli Lilly and Co at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 10:15PM GMT
Release Date Price: C$23.59
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

Good afternoon, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting a fireside chat this afternoon with Eli Lilly. Lilly has obviously had a tremendous few years here and really looking forward to our discussion with Dave Ricks, the company's Chairman and CEO.

So Dave, Happy New Year. Thanks for joining us. I know you're going to make some opening remarks, and then we'll jump into Q&A from there.

David A. Ricks
Eli Lilly and Company - Chairman, CEO & President

Super. Thanks, Chris. Good to be back. Okay. Great. Thank you all for being here, and thanks for that introduction, Chris. I thought I'd give a little bit of a slide presentation because it's been a while since I did that, 2018. So I'll use that as my reference point backwards. That's also the year that Chris Schott put a buy on Lilly. Turned out to work pretty well.

So really, the theme of this is like how can we drive continued R&D and innovation excellence at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot